NASDAQ:BDTX Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis $1.72 -0.07 (-3.65%) As of 02:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Black Diamond Therapeutics Stock (NASDAQ:BDTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BDTX alerts:Sign Up Key Stats Today's Range$1.68▼$1.7750-Day Range$1.25▼$2.0552-Week Range$1.20▼$7.66Volume345,955 shsAverage Volume2.70 million shsMarket Capitalization$97.20 millionP/E RatioN/ADividend YieldN/APrice Target$14.60Consensus RatingBuy Company OverviewBlack Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Read More… Black Diamond Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreBDTX MarketRank™: Black Diamond Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 364th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBlack Diamond Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBlack Diamond Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Black Diamond Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Black Diamond Therapeutics are expected to grow in the coming year, from ($1.30) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Black Diamond Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Black Diamond Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlack Diamond Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Black Diamond Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted18.69% of the float of Black Diamond Therapeutics has been sold short.Short Interest Ratio / Days to CoverBlack Diamond Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Black Diamond Therapeutics has recently decreased by 5.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBlack Diamond Therapeutics does not currently pay a dividend.Dividend GrowthBlack Diamond Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.69% of the float of Black Diamond Therapeutics has been sold short.Short Interest Ratio / Days to CoverBlack Diamond Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Black Diamond Therapeutics has recently decreased by 5.21%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment1.35 News SentimentBlack Diamond Therapeutics has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Black Diamond Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for BDTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Black Diamond Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Black Diamond Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,973,484.00 in company stock.Percentage Held by InsidersOnly 8.87% of the stock of Black Diamond Therapeutics is held by insiders.Percentage Held by Institutions95.47% of the stock of Black Diamond Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Black Diamond Therapeutics' insider trading history. Receive BDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BDTX Stock News HeadlinesPositive week for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) institutional investors who lost 74% over the past yearMay 4 at 12:26 PM | finance.yahoo.comBlack Diamond Therapeutics to Participate in Upcoming Investor ConferencesMarch 31, 2025 | globenewswire.comMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.May 5, 2025 | Weiss Ratings (Ad)Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With ServierMarch 25, 2025 | seekingalpha.comStifel Nicolaus Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)March 21, 2025 | markets.businessinsider.comServier and Black Diamond sign deal for solid tumours therapyMarch 20, 2025 | finance.yahoo.comBlack Diamond, Servier announce global licensing agreement for BDTX-4933March 19, 2025 | markets.businessinsider.comBlack Diamond stock soars on licensing dealMarch 19, 2025 | in.investing.comSee More Headlines BDTX Stock Analysis - Frequently Asked Questions How have BDTX shares performed this year? Black Diamond Therapeutics' stock was trading at $2.14 at the beginning of 2025. Since then, BDTX stock has decreased by 19.9% and is now trading at $1.7150. View the best growth stocks for 2025 here. How were Black Diamond Therapeutics' earnings last quarter? Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) announced its earnings results on Thursday, March, 6th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.03. When did Black Diamond Therapeutics IPO? Black Diamond Therapeutics (BDTX) raised $151 million in an initial public offering (IPO) on Thursday, January 30th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of Black Diamond Therapeutics? Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Black Diamond Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Black Diamond Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Toast (TOST), Meta Platforms (META) and Luminar Technologies (LAZR). Company Calendar Last Earnings3/06/2025Today5/05/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BDTX CIK1701541 WebN/A Phone617-252-0848FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$14.60 High Stock Price Target$20.00 Low Stock Price Target$11.00 Potential Upside/Downside+720.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,440,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-68.08% Return on Assets-49.65% Debt Debt-to-Equity RatioN/A Current Ratio5.55 Quick Ratio5.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.26 per share Price / Book0.79Miscellaneous Outstanding Shares56,677,000Free Float51,566,000Market Cap$100.89 million OptionableOptionable Beta2.63 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:BDTX) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.